Patients for whom targeted radiopharmaceutical therapy would be contraindicated due to underlying medical disorders
Patients with clinically relevant medical history, including autoimmune disease, cardiovascular disease, hepatic disease or bleeding disorders
Any history of hereditary bleeding disorders
Participants with clear evidence of myeloproliferative disorders, or myelodysplastic disorders in the marrow
Uncontrolled electrolyte disorders.
Known immunodeficiency disorders, either primary or acquired
Significant bleeding disorders.
Neurological or psychiatric disorders which may influence understanding of study and informed consent procedures.
Participants will be excluded for medical conditions that are contraindications to XRT and/or might confound the relationship among fatigue, and inflammation, including pregnancy, unstable major psychiatric disorders, autoimmune (active within the past  months) or inflammatory disorders, chronic infectious diseases (e.g. human immunodeficiency virus [HIV], hepatitis B or C), neurologic disorders and uncontrolled cardiovascular, metabolic, pulmonary or renal disease (as determined by medical history, physical examination or laboratory testing) unless otherwise approved by the PI or PIs designee
History of psychiatric drug abuse that cannot be ended, or subjects with mental disorders that will prevent compliance or evaluation including uncontrolled schizophrenia, uncontrolled depression or other uncontrolled disorders.
Participants with inherited or acquired bleeding disorders
Subjects with a history of depression, anxiety, or psychotic disorders (due to tolcapone adverse event profile).
Psychiatric disorders that would interfere with consent
Patients with uncharacterized eye disorders
Patients with known serious mood disorders
Known bleeding disorders
Renal and hepatic disorders with values of >. times the upper limit of normal (ULN) or blood disorders (upon clinician judgment);
HEALTHY SUBJECT: Be free of chronic illness, without known heart, lung, kidney, bleeding disorders, infectious disease (HIV, HBV or HCV infection)
Patients with a history of bleeding disorders
Uncontrolled autoimmune disorders. Patients with autoimmune disorders under control on medication may be included. Patients with pure red cell aplasia may be included if hemoglobin levels are relatively stable on transfusions or medication
Subject has a history of coagulopathies or hematological disorders
Active substance abuse or psychiatric disorders; in case, the patient falls under the lower spectrum of psychiatric disorders and is able to function well under medication, the patient could be accrued at the discretion of the physician
Cardiovascular disorders
Patients with a history of immune-mediated neurological disorders such as multiple sclerosis, Guillain-Barr or inflammatory CNS/PNS disorders
Patients with known disorders associated with hemolysis
Known bleeding disorders
History of thrombocytopenia with complications (including hemorrhage or bleeding ? Grade , based on NCI-CTCAE v. criteria), hemolytic condition, or coagulation disorders that would make subjects unsafe based on the judgment of the Investigator
Patients with active, uncontrolled psychiatric disorders including: psychosis, major depressive, and bipolar disorders
No abnormalities no history of diagnosed acquired bleeding disorders within one year (e.g., acquired anti-factor VIII antibodies) of registration on protocol therapy
Patients with active, uncontrolled psychiatric disorders include: psychosis, major depression, and bipolar disorders
If medical history of the following, case should be reviewed by the Medical Monitor: prior biliary tract disorders (as based on Hepatobiliary SOC high level terms of: obstructive bile duct disorders, hepatic vascular disorders, structural and other bile duct disorders) or portal hypertension and/or hepatic vascular disorders
History or presence of any significant bleeding disorders
Uncontrolled medical or psychiatric disorders
History of significant neurologic or psychiatric disorders including psychotic disorders or dementia that would prohibit the understanding and giving of informed consent
Major medical or psychiatric disorders that would seriously compromise patient tolerance of this regimen
Concurrent or Intercurrent Illness: Impaired wound healing due to diabetes; Significant concurrent or intercurrent illness, psychiatric disorders or alcohol or chemical dependence that would compromise Subject safety or compliance or interfere with interpretation of the study; Uncontrolled thyroid disease or cystic fibrosis; Presence of clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological (with the exception of the presence of hepatitis B virus (HBV), viral hepatitis, or cirrhosis), endocrine, or central nervous system disorders; Current encephalopathy or current treatment for encephalopathy; Variceal bleeding requiring hospitalization or transfusion within  months of screening; History of human immunodeficiency virus or acquired immune deficiency syndrome; The clinical presence of ascites.
History of significant neurological or psychiatric disorders that would impede giving consent, treatment, or follow up.
Patients with personal or family history of bleeding disorders are not eligible
Have a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders.
Uncontrolled electrolyte disorders (eg, hypocalcemia, hypokalemia, hypomagnesemia).
Patients with known history of liver disorders.
Significant hematologic, gastrointestinal, thromboembolic, vascular, bleeding, or coagulation disorders.
Known coagulopathy or bleeding disorders are controlled
Moderate eye disorders
No history of autoimmune disorders
Patients with endometrial disorders, including evidence of endometrial hyperplasia, dysfunctional uterine bleeding or cysts
Autoimmune disorders confined to the skin (e.g. psoriasis) are eligible, and topical steroids are allowed for the treatment of such skin disorders.
Participant has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
Major psychiatric disorders which would limit compliance
Has a history of epilepsy, depression or other psychiatric disorders.
Subject has a contraindication to receiving IM injections (eg, bleeding disorders, anticoagulant use).
History of or current major gastrointestinal, pulmonary, cardiovascular, genitourinary or hematologic disease, CNS disorders, infectious disease or coagulation disorders as determined by the Investigator
Known immunodeficiency disorders
Patients with existing autoimmune disorders (IL- and GM-CSF carry a theoretical clinical risk of exacerbating underlying autoimmune disorders)
Known history of Wilson's disease or other copper-related disorders
Patients with neuromuscular disorders that are associated with elevated CK
Patients with neuromuscular disorders that are associated with elevated CK.
Patients who have a history of bleeding disorders including congenital or acquired coagulopathies
Concurrent uncontrolled or active hepatobiliary disorders, untreated or ongoing complications after laparoscopic procedures or stent placement, including but not limited to active cholangitis, biloma or abscess (to be eligible, the subjects have to be treated and disorders/complications should be resolved within  weeks prior to the first dose of ARQ )
History of significant cardiac disorders:
i. Untreated psychiatric disorders
Patients with active, uncontrolled psychiatric disorders including: psychosis, major depression, and bipolar disorders
Autoimmune disorders
Evidence or history of congenital or acquired hypocoagulability disorders
Patients with uncontrolled coagulopathy or bleeding disorders
Diagnosis of autoimmune disorders
Documented hypercoagulable disorders or vasculopathies
Serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders (including but not limited to connective tissue disorders, lung disease, and cardiac or seizure disorders)
Other preexisting sleep disorders
Patients with a history of/or active bleeding disorders
No known bleeding disorders
Patients with a history of familial bleeding disorders
Has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders
History of significant neurological or psychiatric disorders
History of bleeding disorders
CORTISOL EXCLUSION: Participants with endocrine disorders (e.g., diabetes and thyroid disorders) or on steroid-based medications are excluded from the cortisol portion of the study (with the exception of topical hydrocortisone that is permitted)
Patient has motility/neurologic disorders including autonomic failure (spinal cord lesions, tumor invasion of nerves) and/or poorly controlled endocrine/metabolic disorders (hypercalcemia, hypokalemia, diabetes, hypothyroidism), as determined by the investigator
Subject with known congenital bleeding disorders or platelet dysfunction
Have a current diagnosis of major Axis I psychiatric disorders (e.g. depressive disorders), neurological impairments, or muscular dystrophies
Is known or suspected to have neuromuscular disorders (ex: myasthenia gravis)
Known bleeding disorders
Eating disorders
Treatment for serious psychological disorders (e.g., schizophrenia) in the last  months
Uncontrolled medical or psychiatric disorders
Subjects with metabolic abnormalities (e.g. thyroid disorders, insulin dependent diabetes, rheumatologic disease etc.); subjects with metabolic disorders (a) who are otherwise eligible, (b) treated for hypothyroidism by their primary MD with Synthroid (levothyroxine) and (c) with the approval of the Moffitt treating oncologist will not be excluded from the study
Known cardiac disorders including arrhythmias, hypertension requiring treatment or structural heart disease
Uncontrolled major psychiatric disorders, such as major depression or psychosis
Known bleeding disorders or taking any dose of warfarin or heparin
Known bleeding disorders or taking any dose of warfarin or heparin
Known urea cycle disorders based on history
Patients have a current diagnosis of major Axis I psychiatric disorders, neurological impairments, or muscular dystrophies
The subject has a history of significant bleeding disorders
Uncontrolled coagulopathy or bleeding disorders
Clinical history of severe psychiatric disorders
Bone marrow failure disorders:\r\n* Paroxysmal nocturnal hemoglobinuria (PNH)\r\n* Hereditary bone marrow failure disorders include Diamond-Blackfan anemia, Shwachman- Diamond syndrome, Kostmann syndrome, and congenital amegakaryocytic thrombocytopenia\r\n* Other non-malignant hematologic or immunologic disorders that require transplantation:\r\n** Quantitative or qualitative congenital platelet disorders (including but not limited to congenital megakaryocytopenia, absent-radii syndrome, Glanzmanns thrombasthenia)\r\n** Quantitative or qualitative congenital neutrophil disorders (including but not limited to chronic granulomatous disease, congenital neutropenia)\r\n** Congenital primary immunodeficiencies (including but not limited to severe combined immunodeficiency syndrome, Wiskott-Aldrich syndrome, CD ligand deficiency, T-cell deficiencies)\r\n** Hemoglobinopathies (including sickle cell disease and thalassemia)
Patients with diagnosis of major depression or any other psychiatric disorders
Known bleeding disorders that preclude intramuscular injection (e.g., on anticoagulants or thrombocytopenia)
Significant psychiatric or neurologic disorders that would impair compliance with study protocol
acute rheumatic disorders
The patient has a lack of bleeding disorders, and
Patients must lack bleeding disorders, and be able to provide informed consent; the latter two criteria will be assessed from the patients history and the consenting interview
All patients with existing plasma cell disorders and no history of psychiatric disorders and can receive conscious sedation are eligible to participate in the trial
Participants must lack bleeding disorders, and be able to provide informed consent; the latter two criteria will be assessed from the patients history and the consenting interview
Lack bleeding disorders
Known inherited or acquired bleeding disorders.
Severe cardiac rhythm disorders within the last  days
Bleeding disorders
History of any coagulation, bleeding, or blood disorders (e.g. anemia)
No known bleeding disorders
History or presence of significant bleeding disorders
Has a history of any major neurological disorders, including stroke, multiple sclerosis, or neurodegenerative disease.
not experiencing psychiatric neurological disorders (assessed through clinical team members) that would prevent obtaining consent.
currently experiencing psychiatric or neurologic disorders that would prevent their ability to provide consent.
Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders
Bleeding or thrombotic disorders.
